Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012

Mehra R.Seiwert T.Y.Gupta S.Weiss J.Gluck I.Eder J.P.Burtness B.Tahara M.Keam B.Kang H.Muro K.Geva R.Chung H.C.CHIA-CHI LINAurora-Garg D.Ray A.Pathiraja K.Cheng J.Chow L.Q.M.Haddad R.2022-09-152022-09-1520180007-0920https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049141868&doi=10.1038%2fs41416-018-0131-9&partnerID=40&md5=c920582d26166dd6c806802aaad09418https://scholars.lib.ntu.edu.tw/handle/123456789/620264Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC.[SDGs]SDG3Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012journal article10.1038/s41416-018-0131-9299551352-s2.0-85049141868